Risk Communication advisory committee meeting
This article was originally published in The Tan Sheet
Executive SummaryFDA's Risk Communication advisory committee meeting discusses strategies and lessons from a selection of previously issued FDA communications at a meeting Feb. 25-26 in Silver Spring, Md. Written submissions related to the agenda, which will be posted no later than two business days before the meeting, are due by Feb. 17, according to a Feb. 2 Federal Register 1notice
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.